We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
Read MoreHide Full Article
Key Takeaways
Iovance is expected to report Q3 revenues of $117.7 million and a loss of nine cents per share.
Amtagvi is projected to generate roughly $95 million in sales, making it the key revenue driver.
Proleukin could add $22 million in sales, while investors await updates on pipeline studies.
We expect Iovance Biotherapeutics (IOVA - Free Report) to surpass earnings expectations when it reports third-quarter 2026 results on Nov. 5, before the opening bell. The company’s earnings beat estimates by 35.29% in the last reported quarter.
The Zacks Consensus Estimate for sales is pinned at $117.7 million, while the estimate for earnings is pegged at a loss of 9 cents per share. These estimates point to higher revenues and a narrower loss than in the year-ago quarter.
Factors Likely to Shape IOVA’s Upcoming Results
Iovance currently has two marketed drugs in its portfolio — the IL-2 product Proleukin and the TIL therapy Amtagvi. Proleukin is approved to treat metastatic renal cell carcinoma and metastatic melanoma in adults, while Amtagvi is approved for previously treated advanced melanoma.
Amtagvi is expected to have been the primary driver of Iovance’s third-quarter revenues, accounting for the bulk of the company’s top line. The Zacks Consensus Estimate and our model estimate for the therapy’s sales are both roughly $95 million.
Proleukin is also expected to have contributed to quarterly revenues, with sales potentially benefiting from growing Amtagvi utilization. The drug forms part of the treatment regimen for patients receiving Amtagvi, linking demand for the TIL therapy to sales of the IL-2 product. Management previously stated that Proleukin revenues were expected to grow during the remainder of 2026.
Our model estimate and the Zacks Consensus Estimate for Proleukin sales are both pegged at approximately $22 million.
Investors will also look for updates on Iovance’s pipeline programs. The company is evaluating Amtagvi in combination with Merck’s (MRK - Free Report) Keytruda in the phase III TILVANCE-301 study as a potential treatment for frontline advanced melanoma. The study also serves as the confirmatory trial for the therapy in the currently approved indication. Beyond melanoma, Iovance is developing Amtagvi inseparate clinical studies for non-small cell lung cancer, endometrial cancer and soft tissue sarcomas.
IOVA’s Earnings Surprise History
The company’s earnings beat estimates in three of the trailing four quarters and met estimates on one occasion, delivering an average earnings surprise of 16.82%.
Iovance Biotherapeutics, Inc. Price and EPS Surprise
Year to date, shares of Iovance have surged 211% compared with the industry’s 10% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for IOVA
Per our proven model, companies with both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before their earnings are reported using our Earnings ESP Filter.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
AMRX’s stock has surged about 71% so far this year. Amneal beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter 2026 results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen nearly 23% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter 2026 results on Nov. 3.
View the Zacks #1 Rank List
Image: Bigstock
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
Key Takeaways
We expect Iovance Biotherapeutics (IOVA - Free Report) to surpass earnings expectations when it reports third-quarter 2026 results on Nov. 5, before the opening bell. The company’s earnings beat estimates by 35.29% in the last reported quarter.
The Zacks Consensus Estimate for sales is pinned at $117.7 million, while the estimate for earnings is pegged at a loss of 9 cents per share. These estimates point to higher revenues and a narrower loss than in the year-ago quarter.
Factors Likely to Shape IOVA’s Upcoming Results
Iovance currently has two marketed drugs in its portfolio — the IL-2 product Proleukin and the TIL therapy Amtagvi. Proleukin is approved to treat metastatic renal cell carcinoma and metastatic melanoma in adults, while Amtagvi is approved for previously treated advanced melanoma.
Amtagvi is expected to have been the primary driver of Iovance’s third-quarter revenues, accounting for the bulk of the company’s top line. The Zacks Consensus Estimate and our model estimate for the therapy’s sales are both roughly $95 million.
Proleukin is also expected to have contributed to quarterly revenues, with sales potentially benefiting from growing Amtagvi utilization. The drug forms part of the treatment regimen for patients receiving Amtagvi, linking demand for the TIL therapy to sales of the IL-2 product. Management previously stated that Proleukin revenues were expected to grow during the remainder of 2026.
Our model estimate and the Zacks Consensus Estimate for Proleukin sales are both pegged at approximately $22 million.
Investors will also look for updates on Iovance’s pipeline programs. The company is evaluating Amtagvi in combination with Merck’s (MRK - Free Report) Keytruda in the phase III TILVANCE-301 study as a potential treatment for frontline advanced melanoma. The study also serves as the confirmatory trial for the therapy in the currently approved indication. Beyond melanoma, Iovance is developing Amtagvi inseparate clinical studies for non-small cell lung cancer, endometrial cancer and soft tissue sarcomas.
IOVA’s Earnings Surprise History
The company’s earnings beat estimates in three of the trailing four quarters and met estimates on one occasion, delivering an average earnings surprise of 16.82%.
Iovance Biotherapeutics, Inc. Price and EPS Surprise
Iovance Biotherapeutics, Inc. price-eps-surprise | Iovance Biotherapeutics, Inc. Quote
IOVA Stock Performance
Year to date, shares of Iovance have surged 211% compared with the industry’s 10% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for IOVA
Per our proven model, companies with both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before their earnings are reported using our Earnings ESP Filter.
Iovance currently has an Earnings ESP of +44.44% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks With Favorable Combinations
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
AMRX’s stock has surged about 71% so far this year. Amneal beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter 2026 results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen nearly 23% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter 2026 results on Nov. 3.